Recombinant Cynomolgus Monkey PD-L1/B7-H1 His Protein, CF

When Recombinant Cynomolgus Monkey PD-L1/B7-H1 (Catalog # 10145-B7) is immobilized at 1 µg/mL,Recombinant Cynomolgus Monkey PD-1 Fc Chimera (Catalog # 8578-PD) binds with an ED50 of15-75 ng/mL.

2 μg/lane of Recombinant Cynomolgus Monkey PD‑L1/B7‑H1 His-tag (Catalog # 10145-B7) wasresolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions andvisualized by Coomassie® Blue staining, showing bands at 34-40 kDa.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus Monkey PD-L1/B7-H1 His Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Cynomolgus Monkey PD-L1/B7-H1 is immobilized at 1 µg/mL (100 µL/well), Recombinant Cynomolgus Monkey PD-1 Fc Chimera (Catalog # 8578-PD) binds with an ED₅₀ of 15-75 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived cynomolgus monkey PD-L1/B7-H1 protein
  Met1-Thr239, with a C-teriminal 6-His tag
• Accession #: XP_005581836
• N-terminal Sequence: Phe19
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 26 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 34-40 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus Monkey PD-L1/B7-H1 His Protein, CF

• Avelumab
• B7-H
• B7H1
• B7-H1
• B7H1PDCD1L1
• CD274 antigenMGC142294
• CD274 molecule
• CD274
• PDCD1L1
• PDCD1LG1
• PDCD1LG1MGC142296
• PDL1
• PD-L1
• PD-L1B7 homolog 1
• PDL1PDCD1 ligand 1
• programmed cell death 1 ligand 1
• Programmed death ligand 1

Background

B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1, 2). Mature cynomolgus B7-H1 consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 30 aa cytoplasmic domain. Within the ECD, cynomolgus B7-H1 shares 92%, 72%, and 72% aa sequence identity with human, mouse, and rat B7-H1, respectively. In addition cynomolgus B7-H1 shares 98%, 94%, 94%, 88%, 78%, 98%, 95%, 94%, and 94% aa sequence identity with rhesus macaque, chimpanzee, sumatran orangutan, white-tufted-ear marmoset, Garnett's greater bushbaby, olive baboon, green monkey, western lowland gorilla, and northern white-cheeked gibbon B7-H1, respectively. B7-H1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (3-6), keratinocytes (7, 8), endothelial and intestinal epithelial cells (8, 10), as well as a variety of carcinomas and melanoma (10, 11). B7-H1 is a B7 ligand and binds to B7-1/CD80 and PD-1 receptors on T cells (6, 7, 11-14). It suppresses T cell activation and proliferation (4, 7, 13, 15) and induces the apoptosis of activated Tcells (10). It plays a role in the development of immune tolerance by promoting T cell anergy (6, 13) and enhancing regulatory T cell development (15). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (4, 9) and inhibits the development of Th17 cells (15). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (5, 8, 11, 14). B7-H1/PD-1 coinhibitory pathway was exploited therapeutically resulting in remarkable outcomes with 20-90% response in various types of cancer (16).

1. Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
2. Dong, H. et al. (1999) Nat. Med. 5:1365.
3. Tamura, H. et al. (2001) Blood 97:1809.
4. Chen, L. et al. (2007) J. Immunol. 178:6634.
5. Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
6. Tsushima, F. et al. (2007) Blood 110:180.
7. Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
8. Cao, Y. et al. (2010) Cancer Res. 71:1235.
9. Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
10. Dong, H. et al. (2002) Nat. Med. 8:793.
11. Azuma, T. et al. (2008) Blood 111:3635.
12. Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
13. Park, J.-J. et al. (2010) Blood 116:1291.
14. Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
15. Herold, M. et al. (2015) J. Immunol. 195:3584.
16. Bardhan K. et al. (2016) ; Front Immunol. 7:550

Bioinformatics

• Uniprot:
  • XP_005581836()